Effects of preserved and unpreserved low dose topical atropine eye drops on the ocular surface
Effects of low dose topical 0.01% atropine eye drops with and without benzalkonium chloride (BAK) preservative on the ocular surface in healthy adults
UNSW Sydney
20 participants
Aug 3, 2017
Interventional
Conditions
Summary
Preservatives in eye drops, such as benzalkonium chloride (BAK), are necessary to prevent microbial contamination, but have been known to affect the comfort and health of the eye's structures, especially if used for long periods of time. This study will investigate the impact of BAK in participants using preserved and unpreserved atropine eye drops on their ocular comfort and health, as well as on the action of the drug itself.
Eligibility
Inclusion Criteria6
- Adults aged between 18-40
- Informed consent received
- Have normal eye and general health
- No reported allergy to atropine or preservatives
- Willingness to comply with scheduled visits and other study procedures
- No history of narrow-angle glaucoma or risk of glaucoma
Exclusion Criteria7
- Atropine eye drop use prior to enrollment
- Any ocular disease including inflammation or allergy
- History of allergic reaction to any topical ophthalmic drugs
- Contact lens wearer
- Currently using topical ophthalmic drugs
- Anyone who is taking any form of medication
- Pregnant women, planning to become pregnant, or breast-feeding
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Drug Name: Atropine Sulphate Dose: 1 drop of 0.01% (unpreserved) atropine sulphate eye drops once daily (at night) in each eye Duration: Four weeks Mode of administration: Topical eye drop Adherence Monitoring: Participants will be required to keep a dosage log and to return unused eye drops to monitor adherence
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12617000571370